We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+15.78%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$214M
AUM Growth
+$8.02M
Cap. Flow
-$22.7M
Cap. Flow %
-10.61%
Top 10 Hldgs %
48%
Holding
89
New
17
Increased
13
Reduced
25
Closed
14

Top Buys

Rank Stock Value
1
YARW
Yarrow Bioscience
YARW
+$3.38M
2
INDP icon
Indaptus Therapeutics
INDP
+$2.82M
3
KURA icon
Kura Oncology
KURA
+$1.91M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$1.63M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$1.38M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$3.44M
2
ARGX icon
argenx
ARGX
+$2.88M
3
PODD icon
Insulet
PODD
+$2.82M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$2.72M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.04M

Sector Composition

Rank Sector Weight
1 Healthcare 94.13%
2 Miscellaneous 5.23%
3 Financials 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$27.5M 12.89%
158,675
-22,862
-13% -$3.44M
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$15M 7.04%
96,000
+2,000
+2% +$314K
STXS icon
3
Stereotaxis
STXS
$145M
$10.5M 4.93%
13,680,554
– –
AERI
4
DELISTED
Aerie Pharmaceuticals
AERI
$8.9M 4.17%
131,770
-1,000
-0.8% -$56K
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
$8.54M 4%
306,119
– –
ATRC icon
6
AtriCure
ATRC
$2.47B
$8.53M 3.99%
315,345
-73,800
-19% -$1.73M
ALDR
7
DELISTED
Alder Biopharmaceuticals
ALDR
$6.26M 2.93%
396,013
– –
AKBA icon
8
Akebia Therapeutics
AKBA
$243M
$6.09M 2.85%
610,738
– –
BPMC
9
DELISTED
Blueprint Medicines
BPMC
$5.88M 2.76%
92,691
+4,000
+5% +$318K
DXCM icon
10
DexCom
DXCM
$34.3B
$5.22M 2.45%
220,000
-80,000
-27% -$1.7M
LMNX
11
DELISTED
Luminex Corp
LMNX
$5.02M 2.35%
169,891
-57,609
-25% -$1.48M
ASND icon
12
Ascendis Pharma A/S
ASND
$16.3B
$4.91M 2.3%
73,745
-5,500
-7% -$362K
NBIX icon
13
Neurocrine Biosciences
NBIX
$15.7B
$4.47M 2.09%
45,508
-9,000
-17% -$806K
KURA icon
14
Kura Oncology
KURA
$1.13B
$4.36M 2.04%
239,500
+112,500
+89% +$1.91M
IMMU
15
DELISTED
Immunomedics Inc
IMMU
$4.33M 2.03%
183,000
-97,900
-35% -$1.97M
ZGNX
16
DELISTED
Zogenix, Inc.
ZGNX
$4.32M 2.02%
97,764
+3,500
+4% +$144K
ARNA
17
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.15M 1.94%
95,242
-31,500
-25% -$1.35M
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
$3.95M 1.85%
294,511
-29,332
-9% -$367K
LKFT
19
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$3.74M 1.75%
40,609
+1,000
+3% +$97K
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.51B
$3.46M 1.62%
604,652
-370,000
-38% -$2.04M
IBB icon
21
iShares Biotechnology ETF
IBB
$10.5B
$2.87M 1.34%
26,100
– –
XENE icon
22
Xenon Pharmaceuticals
XENE
$5.81B
$2.71M 1.27%
294,362
-83,333
-22% -$518K
ACHN
23
DELISTED
Achillion Pharmaceuticals
ACHN
$2.68M 1.26%
947,636
+79,364
+9% +$270K
VBIV
24
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$2.57M 1.2%
31,156
-2,111
-6% -$204K
YARW
25
Yarrow Bioscience
YARW
$98.8M
$2.53M 1.19%
+87
New +$3.38M
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, DAFNA Capital Management held 89 positions worth $214M, up 3.9% from $206M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $22.7M in Q2 2018, closing 14 positions and reducing 25 holdings. Its most notable exit was Insulet, an estimated $2.82M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, DAFNA Capital Management opened a new position in Yarrow Bioscience worth $2.53M.

  • DAFNA Capital Management's largest Q2 2018 buy was Yarrow Bioscience: 87 shares worth $2.53M.
  • DAFNA Capital Management added most to Kura Oncology in Q2 2018, an estimated $1.91M increase.
  • DAFNA Capital Management's biggest Q2 2018 reduction was Loxo Oncology, Inc, cutting an estimated $3.44M.
  • DAFNA Capital Management fully exited Insulet in Q2 2018, selling an estimated $2.82M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $214M portfolio in Q2 2018.
  • DAFNA Capital Management opened 17 new positions and closed 14 in Q2 2018.
  • DAFNA Capital Management's portfolio value rose 3.9% quarter-over-quarter to $214M.

Based on DAFNA Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.